APRI (Aprinoia Therapeutics) Change In Receivables: $0.00 Mil (TTM As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aprinoia Therapeutics Change In Receivables?

Aprinoia Therapeutics APRI Change In Receivables is $0.00 Mil as of Dec. 2023.

Aprinoia Therapeutics's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Aprinoia Therapeutics's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

Aprinoia Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.07 Mil. It means Aprinoia Therapeutics's Accounts Receivable increased by $0.07 Mil from Dec. 2022 to Dec. 2023 .

Aprinoia Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.07 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Aprinoia Therapeutics's Days Sales Outstanding for the six months ended in Dec. 2023 was 370.21.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Aprinoia Therapeutics's liquidation value for the six months ended in Dec. 2023 was $-103.80 Mil.

Aprinoia Therapeutics  (NAS:APRI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Aprinoia Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.071/0.035*91
=370.21

2. In Ben Graham's calculation of liquidation value, Aprinoia Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Aprinoia Therapeutics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=1.578-105.435+0.75 * 0.071+0.5 * 0
=-103.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Change In Receivables Related Terms

Aprinoia Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Change In Receivables Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Change In Receivables
-0.16 0.15 -0.07

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Change In Receivables 0.00 -0.05 0.20 0.00 0.00

Aprinoia Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.00 Mil mean?
Aprinoia Therapeutics (APRI) has a Change In Receivables of $0.00 Mil as of Dec. 2023. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Change In Receivables too high?
Aprinoia Therapeutics' current Change In Receivables is $0.00 Mil.
How does Aprinoia Therapeutics' Change In Receivables compare to ?
Aprinoia Therapeutics' Change In Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Change In Receivables is $0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.